COMPARATIVE PHARMACOKINETICS OF TEMAZEPAM GELTHIX AND LIQUID-FILLED SOFT GELATIN CAPSULES

被引:1
作者
DRAKE, J
FREEDMAN, PS
HAWKINS, BC
HORTH, CE
LAUNCHBURY, AP
WHATELEYSMITH, C
机构
[1] FARMITALIA CARLO ERBA LTD,ITALIA HOUSE,23 GROSVENOR RD,ST ALBANS AL1 3AW,HERTS,ENGLAND
[2] HINCHINGBROOKE HOSP,CLIN SCI RES LTD,CAMBRIDGE,ENGLAND
[3] LIFE SCI RES LTD,EYE,SUFFOLK,ENGLAND
关键词
D O I
10.1111/j.1365-2710.1991.tb00324.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An open, randomized, cross-over study involving 24 healthy volunteers, shows that a novel formulation of temazepam (temazepam Gelthix, TG) in soft gelatin capsules designed to resist i.v. abuse has a similar pharmacokinetic (P-K) profile to that of a liquid-filled, reference formulation (TL) when administered as a single oral dose of 20 mg. The relative bioavailability of the two formulations assessed in terms of the area under the time versus plasma concentration profile (AUC), although statistically different (P < 0.05), is well within the acceptable 80-120% limits for bioequivalence. Although the mean C(max) for TG (616.6 ng/ml) is lower than for TL (707.9 ng/ml) and the median time to reach C(max) (T(max) is 40 min (TG) vs. 30 min (TL), there is no significant difference between TG and TL either in their absorption constant (K(a)) (0.123 vs. 0.138 min-1 respectively) or their distribution (a) (29.5 vs. 32.4 min) and elimination (beta) (6.3 vs. 6.6 h) half-lives (t1/2). Thus the essential P-K characteristics for the use of temazepam as a hypnotic and premedicant, specifically a rapid rise followed by a prompt fall in blood levels, are conserved by the Gelthix formulation.
引用
收藏
页码:345 / 351
页数:7
相关论文
共 14 条
  • [1] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF BENZODIAZEPINES IN HUMAN-PLASMA
    BRODIE, RR
    CHASSEAUD, LF
    TAYLOR, T
    [J]. JOURNAL OF CHROMATOGRAPHY, 1978, 150 (02): : 361 - 366
  • [2] MISUSE OF TEMAZEPAM
    FARRELL, M
    STRANG, J
    [J]. BRITISH MEDICAL JOURNAL, 1988, 297 (6660) : 1402 - 1402
  • [3] FUCELLA LM, 1977, EUROPEAN J CLIN PHAR, V12, P383
  • [4] FUCELLA LM, 1972, INT J CLIN PHARM TH, V6, P303
  • [5] Gibaldi M, 1975, PHARMACOKINETICS, P281
  • [6] HINDMARCH I, 1975, ARZNEIMITTEL-FORSCH, V25, P1836
  • [7] LAU CE, 1987, J CHROMATOGR-BIOMED, V60, P212
  • [8] LAUNCHBURY AP, 1988, LANCET, V1, P1113
  • [9] LAUNCHBURY AP, 1989, MANUFACTUR CHEM, V69, P38
  • [10] LAUNCHBURY AP, 1990, PHARM J, V244, P749